Advisory Resource Group Makes New $946,000 Investment in AstraZeneca PLC (NASDAQ:AZN)

Advisory Resource Group purchased a new stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 12,143 shares of the company's stock, valued at approximately $946,000.

Other large investors have also modified their holdings of the company. Stratos Wealth Advisors LLC raised its holdings in shares of AstraZeneca by 2.0% in the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company's stock valued at $522,000 after buying an additional 133 shares during the period. Carnegie Investment Counsel increased its holdings in AstraZeneca by 0.8% during the 2nd quarter. Carnegie Investment Counsel now owns 17,269 shares of the company's stock worth $1,347,000 after purchasing an additional 138 shares during the period. Crumly & Associates Inc. increased its holdings in AstraZeneca by 2.2% during the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company's stock worth $518,000 after purchasing an additional 143 shares during the period. Sunpointe LLC increased its holdings in AstraZeneca by 4.5% during the 2nd quarter. Sunpointe LLC now owns 3,419 shares of the company's stock worth $267,000 after purchasing an additional 147 shares during the period. Finally, Argonautica Private Wealth Management Inc. increased its holdings in AstraZeneca by 4.0% during the 2nd quarter. Argonautica Private Wealth Management Inc. now owns 3,874 shares of the company's stock worth $302,000 after purchasing an additional 149 shares during the period. Institutional investors and hedge funds own 20.35% of the company's stock.

Analysts Set New Price Targets

AZN has been the topic of several recent research reports. UBS Group upgraded AstraZeneca from a "sell" rating to a "neutral" rating in a report on Wednesday, November 20th. Erste Group Bank upgraded AstraZeneca from a "hold" rating to a "buy" rating in a report on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a "sell" rating to a "hold" rating in a report on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of "Moderate Buy" and an average price target of $89.75.

AstraZeneca Stock Down 0.6 %

Shares of AZN traded down $0.38 during mid-day trading on Thursday, reaching $67.02. The company's stock had a trading volume of 2,350,443 shares, compared to its average volume of 5,304,312. The stock has a market cap of $207.80 billion, a PE ratio of 32.25, a price-to-earnings-growth ratio of 1.20 and a beta of 0.45. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The company's 50 day moving average is $70.61 and its 200 day moving average is $76.86.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to analysts' expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business's revenue was up 18.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.87 EPS. Equities analysts anticipate that AstraZeneca PLC will post 4.11 EPS for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.